FY2025 Earnings Forecast for ACADIA Pharmaceuticals Inc. Issued By Zacks Research (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $0.93 per share for the year, down from their prior estimate of $0.94. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.62 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q1 2026 earnings at $0.41 EPS and FY2026 earnings at $1.28 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.04). The company had revenue of $231.04 million during the quarter, compared to analyst estimates of $223.79 million. ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. ACADIA Pharmaceuticals’s revenue for the quarter was up 69.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.26) earnings per share.

Other equities analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 28th. StockNews.com upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. Oppenheimer reissued a “market perform” rating and set a $25.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, February 5th. Mizuho downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $39.00 to $25.00 in a research note on Tuesday, March 12th. Finally, JPMorgan Chase & Co. lowered their price target on shares of ACADIA Pharmaceuticals from $29.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, March 25th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $35.82.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD opened at $16.99 on Tuesday. The firm’s 50-day simple moving average is $20.64 and its 200 day simple moving average is $23.72. The firm has a market cap of $2.80 billion, a P/E ratio of -44.71 and a beta of 0.37. ACADIA Pharmaceuticals has a 52 week low of $16.60 and a 52 week high of $33.99.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, insider James Kihara sold 1,790 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $17.87, for a total transaction of $31,987.30. Following the sale, the insider now owns 13,100 shares of the company’s stock, valued at $234,097. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider James Kihara sold 1,790 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.87, for a total transaction of $31,987.30. Following the sale, the insider now directly owns 13,100 shares in the company, valued at approximately $234,097. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Stephen Davis sold 26,574 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, April 8th. The stock was sold at an average price of $17.87, for a total transaction of $474,877.38. Following the transaction, the chief executive officer now owns 144,267 shares in the company, valued at approximately $2,578,051.29. The disclosure for this sale can be found here. Insiders sold a total of 69,383 shares of company stock worth $1,291,362 in the last three months. 27.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. RTW Investments LP increased its position in ACADIA Pharmaceuticals by 18.3% during the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock valued at $241,255,000 after purchasing an additional 1,793,288 shares during the period. Norges Bank bought a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at about $45,187,000. Fred Alger Management LLC boosted its holdings in ACADIA Pharmaceuticals by 38.7% in the third quarter. Fred Alger Management LLC now owns 3,108,883 shares of the biopharmaceutical company’s stock worth $64,789,000 after acquiring an additional 867,818 shares in the last quarter. Eventide Asset Management LLC acquired a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $25,342,000. Finally, M&G Investment Management Ltd. acquired a new position in shares of ACADIA Pharmaceuticals during the fourth quarter valued at about $10,349,000. 96.71% of the stock is currently owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.